CGTX — Cognition Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB
Cognition Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cognition Therapeutics Q2 net loss narrows on lower R&D costs
Cognition Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Cognition Therapeutics Q1 net loss narrows on lower expenses
Cognition Therapeutics 2025 net loss narrows as expenses fall
Brief: Cognition Therapeutics Advancing Zervimesine (Ct1812) For Dementia With Lewy Bodies (DLB) Psychosis
U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF Bankshares
U.S. STOCKS ON THE MOVE-OneSpaWorld, IMUNON, Cigna
Cognition Therapeutics rises as it extends access to rare brain disorder drug
Brief: Cognition Therapeutics Extends Expanded Access Program For Zervimesine (Ct1812) In Dementia With Lewy Bodies
Brief: Cognition Therapeutics Outlines Phase 3 Alzheimer's Plan at CTAD
Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division
Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs
Brief: Cognition Therapeutics Study Of Zervimesine (Ct1812) In Early Alzheimer’S Disease Reaches 75% Enrollment Target
Cognition Therapeutics slides after announcement of $30 million direct stock deal